相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling
Pablo Zubiaur et al.
CLINICAL PHARMACOKINETICS (2021)
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions
Xia Li et al.
CLINICAL PHARMACOKINETICS (2020)
Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment
Francoise Stanke-Labesque et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal Cells
Florian Simon et al.
AAPS JOURNAL (2019)
Inflammation is a potential risk factor of voriconazole overdose in hematological patients
Elodie Gautier-Veyret et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2019)
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations
Krishna K. Machavaram et al.
AAPS JOURNAL (2019)
Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance
David E. Coutant et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
Nina Hanke et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes
Marie Febvre-James et al.
DRUG METABOLISM AND DISPOSITION (2018)
Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
Eun Bong Lee et al.
CLINICAL PHARMACOKINETICS (2017)
Voriconazole metabolism is influenced by severe inflammation: a prospective study
Anette Veringa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole
Fang Qi et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations
Elodie Gautier-Veyret et al.
PHARMACOGENOMICS (2017)
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6
Xiling Jiang et al.
AAPS JOURNAL (2016)
Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children
Nienke J. Vet et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole
Nicolas Hohmann et al.
CLINICAL PHARMACOKINETICS (2016)
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
Haiying Jin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Evaluation of Disease-Mediated Therapeutic Protein-Drug Interactions Between an Anti-Interleukin-6 Monoclonal Antibody (Sirukumab) and Cytochrome P450 Activities in a Phase 1 Study in Patients With Rheumatoid Arthritis Using a Cocktail Approach
Yanli Zhuang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
Y. Xu et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
A Systematic Comparison of the Impact of Inflammatory Signaling on Absorption, Distribution, Metabolism, and Excretion Gene Expression and Activity in Primary Human Hepatocytes and HepaRG Cells
Marcus Klein et al.
DRUG METABOLISM AND DISPOSITION (2015)
Inflammation Is Associated with Voriconazole Trough Concentrations
Marjolijn J. P. van Wanrooy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
Michael J. Dolton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates
Sylvain Goutelle et al.
AAPS JOURNAL (2013)
A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease-Drug Interactions: Suppression of CYP3A by IL-6
K. K. Machavaram et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes
S. Martis et al.
PHARMACOGENOMICS JOURNAL (2013)
Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture
Leslie J. Dickmann et al.
CURRENT DRUG METABOLISM (2012)
Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory
Charles M. Strom et al.
GENETICS IN MEDICINE (2012)
Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use
Bharat Damle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Disease-Drug-Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis
C. Schmitt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential
Eugenia Kraynov et al.
DRUG METABOLISM AND DISPOSITION (2011)
Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture
Leslie J. Dickmann et al.
DRUG METABOLISM AND DISPOSITION (2011)
Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients
Claudia Michael et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-α or Interleukin-6
Marc Le Vee et al.
DRUG METABOLISM AND DISPOSITION (2009)
Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis
Sheila Annie Peters
CLINICAL PHARMACOKINETICS (2008)
The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease
PA McArdle et al.
BRITISH JOURNAL OF CANCER (2004)
Serum albumin: Relationship to inflammation and nutrition
BR Don et al.
SEMINARS IN DIALYSIS (2004)
分享论文
